← Back to Search

Screening (biospecimen collection) for Prostate Cancer

N/A
Recruiting
Led By Heather H. Cheng
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years
Awards & highlights

Summary

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Positive predictive values (PPVs) of age-based prostate specific antigen (PSA) thresholds

Trial Design

1Treatment groups
Experimental Treatment
Group I: Screening (biospecimen collection)Experimental Treatment4 Interventions
Participants undergo collection of blood, urine, and/or tissue samples every 12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,550 Total Patients Enrolled
566 Trials studying Prostate Cancer
529,359 Patients Enrolled for Prostate Cancer
CureBRCAUNKNOWN
Canary FoundationOTHER
4 Previous Clinical Trials
4,204 Total Patients Enrolled
~260 spots leftby Aug 2030